Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020672 (
hypothermia
)
17,327
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It is well known that cold and diet-induced thermogenesis, which is mediated in small rodents by the hypothalamic-noradrenergic fibers-brown adipose tissue axis, is impaired in genetically obese mice. To test whether these adaptive mechanisms are also impaired in obese humans, 12 young males who were otherwise healthy (6 lean and 6 obese) were examined. The obese subjects had an early-onset type of obesity with a strong family history of it as well. Deep body temperature was measured by using a deep body thermometer furnished with three thermocouples. They were respectively placed on the sternum, on the interscapular area immediately under the neck (HIS), and on the 4th intercostal space (
LIS
) in order to study core temperature as well as heat production where brown adipose tissue could also be present in adults. Both lean and obese subjects were kept in a thermoneutral environment (28 degrees C) until they reached a steady-state body temperature and then rapidly transferred into a cold room (6-8 degrees C) where they remained up to 60 min.
Body temperature decreased
in both groups, but the decrease was more marked in the obese individuals on the sternum (P less than 0.01), on HIS (P less than 0.05) and on
LIS
(P less than 0.05) when compared to lean individuals. In conclusion, cold-induced thermogenesis is impaired in familial early-onset human obesity and in genetically obese mice.
...
PMID:Reduced cold-induced thermogenesis in familial human obesity. 395 96
2-Bromolisuride (2-Br-LIS), a derivative of the ergot dopamine (DA) agonist lisuride, was investigated in rodents in comparison with the DA antagonist haloperidol with regard to its influence on DA related behaviour, cerebral DA metabolism and prolactin (PRL) secretion. 2-Br-
LIS
produced catalepsy in mice (ED50 3.3 mg/kg i.p.), antagonized apomorphine-induced stereotypies in mice (ED50 0.4 mg/kg i.p.), antagonized DA agonist-induced stereotypies in rats (0.1-1.56 mg/kg i.p.), inhibited locomotor activity in rats (0.025-6.25 mg/kg i.p.), antagonized the hyperactivity produced by various DA agonists in rats (0.025-6.25 mg/kg i.p.) and inhibited the apomorphine-induced
hypothermia
in mice (0.05-0.78 mg/kg i.p.). 2-Br-
LIS
(0.03-10 mg/kg i.p.) stimulated DA biosynthesis and DOPAC formation in the striatum and DA rich limbic system of rats, but had no effect on serotonin turnover. In striatum and limbic forebrain of gamma-butyrolactone-pretreated rats 2-Br-
LIS
reversed the apomorphine-induced inhibition of DOPA accumulation. 2-Br-
LIS
(0.03 - 3 mg/kg) enhanced PRL secretion in intact male rats. These findings indicate DA antagonistic properties of 2-Br-
LIS
presumably due to blockade of central pre- and postsynaptic DA receptors being of approximately the same order of potency as haloperidol. 2-Br-
LIS
is the first ergot compound with definite antidopaminergic properties suggesting its potential usefulness as a neuroleptic.
...
PMID:Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride. 660 92